According to GlobalData’s company profile on Jazz Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Jazz Pharmaceuticals‘s grant share as of February 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Cbd preparation with at least 90% cbd and thc
A recently granted patent (Publication Number: US11865102B2) discloses a cannabidiol (CBD) preparation with a high concentration of CBD, greater than or equal to 90% (w/w) based on the total amount of cannabinoids in the preparation. The remaining cannabinoids in the preparation include tetrahydrocannabinol (THC), present as a mixture of trans-THC and cis-THC, with a specific ratio ranging from about 0.7:1.0 to about 5.0:1.0. Additionally, the CBD preparation contains not more than 1.5% (w/w) THC, with specific ranges of THC content specified in the claims.
Furthermore, the patent covers the use of this CBD preparation in pharmaceutical compositions for treating epilepsy, specifically targeting conditions such as Dravet syndrome, Lennox Gastaut syndrome, Doose syndrome, or tuberous sclerosis complex (TSC). The method involves administering a therapeutically effective amount of the CBD preparation, with specified dosage ranges from about 5 mg/kg/day to…
